cis-(+/-)-1,2-epoxy-4-(hydroxymethyl)cyclopentane | 72598-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: cis-(+/-)-1,2-epoxy-4-(hydroxymethyl)cyclopentane
• 英文别名: syn-6-Oxabicyclo[3.1.0]hexane-3-methanol；syn-3-(Hydroxymethyl)-6-oxabicyclo[3.1.0]hexane
• CAS: 72598-06-2
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: ZWMXHPOWONDHGL-FPFOFBBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.16
• 重原子数：
  8.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.76
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  cis-(+/-)-1,2-epoxy-4-(hydroxymethyl)cyclopentane 在 咪唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 Lithium (S)-2-(1-pyrrolidinylmethyl)pyrrolidide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 (1S,4R)-(+)-4-(tert-butyldimethylsilanyloxymethyl)cyclopent-2-enol
  参考文献：
  名称：

  An asymmetric synthesis of (−)-carbovir

  摘要：

  Enantioselective deprotonation of trans-4-t-butyldimethylsiloxymethyl-1,2-epoxycyclopentane (trans-4) by a chiral lithium amide, lithium (S)-2-(pyrrolidin-1-ylmethyl)pyrrolidide (1), afforded (1S,4S)-trans-4-t-butyldimethylsiloxymethyl-2-cyclopenten-1-ol (trans-7) in 83 %ee. Alcohol trans-7 was easily transformed to (-)-carbovir, an anti-HIV carbocyclic nucleoside.

  DOI：

  10.1016/0957-4166(94)80072-3
• 作为产物：
  描述：

  二烯丙基丙二酸二甲酯 在 Grubbs catalyst first generation 、 bis(acetylacetonate)oxovanadium 叔丁基过氧化氢 、 lithium aluminium tetrahydride 、 lithium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 124.0h， 生成 cis-(+/-)-1,2-epoxy-4-(hydroxymethyl)cyclopentane
  参考文献：
  名称：

  A Flexible, Efficient Synthesis of (±)-Carbocyclic Phosphonic Acid Nucleoside Derivatives

  摘要：

  本文介绍了一种高效灵活的环戊烷和羟化环戊烷膦酸类似物的合成方法。关键步骤是用核苷碱或硒阴离子打开环氧化物，以获得目标分子。

  DOI：

  10.1055/s-2005-863745

文献信息

• Heteroaryl compounds useful as inhibitors of E1 activating enzymes
  申请人：Claiborne F. Christopher

  公开号：US20080051404A1

  公开（公告）日：2008-02-28

  This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

  这项发明涉及抑制E1激活酶的化合物，包括这些化合物的药物组合物，以及使用这些化合物的方法。这些化合物可用于治疗疾病，特别是细胞增殖性疾病，包括癌症、炎症和神经退行性疾病；以及与感染和虚弱相关的炎症。
• Synthesis and Biological Evaluation of 2‘,3‘-Didehydro-2‘,3‘-dideoxy-5- fluorocytidine (D4FC) Analogues:  Discovery of Carbocyclic Nucleoside Triphosphates with Potent Inhibitory Activity against HIV-1 Reverse Transcriptase
  作者：Junxing Shi、J. Jeffrey McAtee、Susan Schlueter Wirtz、Phillip Tharnish、Amy Juodawlkis、Dennis C. Liotta、Raymond F. Schinazi

  DOI：10.1021/jm980510s

  日期：1999.3.1

  beta-D-D4FC was not active against HIV-1, even at 100 microM. The carbocyclic analogues (26a,b) of D4FC demonstrated weak activity against HIV-1 and no toxicity in various cells. The triphosphates (27a,b) of the carbocyclic nucleosides demonstrated potent inhibitory activity against recombinant HIV-1 reverse transcriptase at submicromolar concentrations. Of the compounds tested as potential anticancer

  发现了新型胞嘧啶核苷β-D-2'，3'-didehydro-2'，3'-二脱氧-5-氟胞苷（D-D4FC）作为有效的抗人免疫缺陷病毒（HIV）药物，这导致我们合成了一系列β-D-D4FC的类似物和衍生物，它们可能更具选择性，并且具有增强的糖苷键稳定性。评价合成的D-D4FC类似物在各种细胞中的抗HIV-1活性，抗癌活性和细胞毒性。生物学数据表明，β-D-D4FC被溴（6c）和碘（6d）5取代导致抗病毒活性丧失，并且D-D4FC的α-D异头物（7a）也没有活动。与母体化合物相比，D-D4FC的5-氟尿嘧啶类似物（6b和7b）效力更低，细胞毒性更高，而β-L-D4FU（11）则显示出强大的抗HIV-1活性和细胞毒性。β-D-D4FC的N4-和5'-O-酰基衍生物（17，15a-c）表现出与β-D-D4FC相当的抗病毒活性。相反，β-D-D4FC的N4-异丙基衍生物（20）即使在100 micr
• Concerning the synthesis and enantioselective rearrangements of episulfoxides
  作者：Alexander J. Blake、Paul A. Cooke、Jackie D. Kendall、Nigel S. Simpkins、Susan M. Westaway

  DOI：10.1039/a908391j

  日期：——

  A novel synthesis of episulfoxides having the norbornane skeleton is possible by use of a rhodium catalyst to effect SO transfer from trans-stilbene episulfoxide to norbornene or norbornadiene. Analogous Rh2(OAc)4 catalysed sulfur transfer to these alkenes is also possible using propylene sulfide as the sulfur source. These methods did not give useful yields of products with alternative types of alkene substrate. A novel type of chiral lithium amide base reaction, involving the rearrangement of certain types of symmetrical ring-fused episulfoxides, gives alkenyl sulfoxide products in up to 88% ee. The structures of the products, including absolute stereochemistry, were assigned based on X-ray crystal structure determinations. p

  一种新的合成具有诺尔博烯骨架的环氧亚硫酸酯的方法是通过使用铑催化剂，使转式苯乙烯环氧亚硫酸酯向诺尔博烯或诺尔博烯二烯转移SO。类似的Rh2(OAc)4催化的硫转移也可以使用丙烯硫醚作为硫源。这些方法对于其他类型的烯烃底物并未产生有用的产品产率。 一种新型的手性锂胺碱反应，涉及某些类型对称环连接的环氧亚硫酸酯的重排，能以高达88%的对映选择性获得烯基亚硫酸酯产品。产品的结构，包括绝对立体化学，是基于X射线晶体结构测定进行的指认。
• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
  申请人：Claiborne Christopher F.

  公开号：US20120071482A1

  公开（公告）日：2012-03-22

  This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

  本发明涉及抑制E1激活酶的化合物、包含该化合物的制药组合物以及使用该化合物的方法。该化合物可用于治疗疾病，特别是细胞增殖性疾病，包括癌症、炎症和神经退行性疾病；以及与感染和消瘦相关的炎症。